<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[King Pharmaceuticals Inc. | Company News & Executive Profiles - KG | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/king+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for King Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="37" />
	<language>en-us</language>
	<item>
		<title><![CDATA[King Pharmaceuticals Financial Gauge Analysis for September 2009 Quarter]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F175696-king-pharmaceuticals-financial-gauge-analysis-for-september-2009-quarter%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Neil Carvin submits:   In a previous article, we examined King Pharmaceuticals' (NYSE: KG)  Income Statement for the third quarter of 2009  and compared the entries on each line to our  "look-ahead" estimates.  Earnings in this period, which ended 30 September 2009, fell from $0.34...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 30 Nov 2009 04:09:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/neil+carvin.html"><![CDATA[Neil Carvin]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharma Marches Higher]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F174541-king-pharma-marches-higher%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[optionMONSTER submits:  By David Russell Call volume surged in King Pharmaceuticals KG yesterday as the drugmaker continued to march higher. by optionMONSTER]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 20 Nov 2009 08:27:49 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/optionmonster.html"><![CDATA[optionMONSTER]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharma Income Statement Analysis for September 2009 Quarter]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F172136-king-pharma-income-statement-analysis-for-september-2009-quarter%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Neil Carvin submits:  King Pharmaceuticals, Inc. (NYSE: KG) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year.   On a non-GAAP ("pro forma" or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 09 Nov 2009 12:57:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/neil+carvin.html"><![CDATA[Neil Carvin]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: King Pharmaceuticals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F171192-earnings-preview-king-pharmaceuticals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[King Pharmaceuticals KG is expected to report Q3  earnings Thursday, November 5 before market open, with a conference call  scheduled for 11:00 am ET.  Guidance Analysts are looking for EPS of 27c on revenue of  $444.98M. The consensus range is 22c-33c for EPS, and $415M-$458.5M for...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 04 Nov 2009 09:39:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharma Look-Ahead to September 2009 Quarterly Results]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163390-king-pharma-look-ahead-to-september-2009-quarterly-results%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Neil Carvin submits:   The GCFR Overall Gauge of King Pharmaceuticals (NYSE: KG) dropped from 28 to 18 of the 100 possible points in the second quarter of 2009. Our income statement and financial gauge analysis reports explained this result in some detail. by Neil Carvin]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 25 Sep 2009 03:04:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/neil+carvin.html"><![CDATA[Neil Carvin]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharmaceuticals Launches Recently Approved Pain Med]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163241-king-pharmaceuticals-launches-recently-approved-pain-med%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Earlier this week, King Pharmaceuticals, Inc. KG announced the launch of Embeda, which recently received U.S. Food and Drug Administration FDA approval for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.  Embeda,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 24 Sep 2009 08:38:54 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharma Financial Gauge Analysis for June 2009 Quarter]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156698-king-pharma-financial-gauge-analysis-for-june-2009-quarter%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Neil Carvin submits:   In an earlier post, we examined King Pharmaceuticals' (NYSE: KG)  Income Statement for the three months that ended 30 June 2009.  Second-quarter earnings fell from $0.17 last year to $0.15 per share.  Non-GAAP earnings per share slipped from $0.35 to $0.32. by...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 18 Aug 2009 03:00:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/neil+carvin.html"><![CDATA[Neil Carvin]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharma Gets a Boost]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F156204-king-pharma-gets-a-boost%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   King Pharmaceuticals Inc. KG recently received the US Food and Drug Administration&#8217;s FDA approval for marketing Embeda, its new drug for moderate to severe chronic pain. The company plans to launch the product next month. Embeda is made of morphine and naltrexone, with morphine being its...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 14 Aug 2009 10:18:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F154666-king-pharmaceuticals-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[King Pharmaceuticals, Inc. KG   Q2 2009 Earnings Call Transcript   August 6, 2009 11:00 pm ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 07 Aug 2009 07:08:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
	<item>
		<title><![CDATA[King Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-329666.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator instructions Our first question comes from the line of Louise Chen of Collins Stewart. Please state your question. Louise Chen -- Collins Stewart My question was with respect to your abuse-deterrent opioid franchise. Based on comments made by the FDA, it sounds like they do want...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 07 Aug 2009 06:08:19 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/agency.html"><![CDATA[Agency]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/king+pharmaceuticals+inc..html"><![CDATA[King Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/advertising+%2526+promotion.html"><![CDATA[Advertising & Promotion]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">KG</category>
		<category domain="tickers">KG</category>
	</item>
</channel>
</rss>
